Investigation Report on Chinese Sorafenib Market, 2018-2022
|発行||China Research and Intelligence||商品コード||335239|
|出版日||ページ情報||英文 30 Pages
|中国のソラフェニブ市場の分析 Investigation Report on Chinese Sorafenib Market, 2018-2022|
|出版日: 2018年07月11日||ページ情報: 英文 30 Pages||
Sorafenib is mainly used to treat inoperable advanced renal cell carcinoma and inoperable or metastasized primary hepatocellular carcinoma. Sorafenib was jointly developed by Bayer and ONYX. In 2006, the drug was approved to be imported to China. In 2008, it entered China after the liver cancer indication was approved by the CFDA.
Liver cancer is the sixth most common cancer in the world and the second leading cause of cancer-related death. It is estimated that over 800 thousand cases of liver cancer are diagnosed worldwide (more than 400 thousand cases in China) every year with a continuous increase in incidence. In 2012, around 746 thousand people died of liver cancer, including 383 thousand deaths in China. As the most effective targeted drug for liver cancer, Sorafenib brings hope to numerous tumor patients.
According to CRI, Sorafenib has been growing since it entered China. In 2017, its sales value in China was about CNY 195 million. Currently, Sorafenib legally sold in China are all Bayer's products.
According to CRI, cancer incidence continues to rise in China because of aggravating environmental pollution and changing lifestyle. Therefore, there will be a great demand for Sorafenib. After several links of circulation, Bayer's Sorafenib is so high-priced that many low-income patients cannot afford it. Some patients choose to purchase Sorafenib produced by Indian enterprises such as NATCO and smuggled to China because the price is only 2%-3% of that of Bayer's Sorafenib. Some Chinese enterprises has also started the development of generic drugs.
It is possible that China-made Sorafenib will appear on the market after 2022.